View Post

Rare Patient Voice: Hepatocellular Carcinoma

In Paid Opportunities For The Cancer Community by Barbara Jacoby

Study Details: Patients and caregivers 60- min phone interview $100 compensation https://rarepatientvoice.com/for-patients/patient-and-caregiver-sign-up/ About Rare Voice Rare Patient Voice is a market research company that helps patients and caregivers voice their opinions, through confidential interviews and surveys, to improve medical products and services. Patients and caregivers receive cash rewards for participating. To show our appreciation, we will send you a gift …

View Post

Cancer patients find clinical trials, hope and help

In Clinical Trials by Barbara Jacoby

By: Diane Mapes From: fredhutch.org #NWMetsConf connects metastatic breast cancer patients with trials, treatments, tools and each other Clinical trials — the treatments of tomorrow, today — took top billing at the fourth annual Northwest Metastatic Breast Cancer Conference held Saturday at the Amazon Meeting Center in Seattle. Scientists from Fred Hutchinson Cancer Research Center shared new treatments; National Cancer …

View Post

Researchers discover coffee drinkers could halve their risk of liver cancer

In In The News by Barbara Jacoby

From: Queen’s University Belfast A research team from Queen’s University Belfast has found that coffee drinkers have a lower risk of the most common type of liver cancer, hepatocellular carcinoma (HCC). The results have been presented at the National Cancer Research Institute (NCRI) conference in Glasgow this week and was published in British Journal of Cancer earlier this year. Coffee is one …

View Post

Rare Patient Voice: Non-small cell lung cancer patients

In Paid Opportunities For The Cancer Community by Barbara Jacoby

Study Details: Metastatic only- stages IIIa, IIIb, IV Online Survey 20 min for $35 https://rarepatientvoice.com/for-patients/patient-and-caregiver-sign-up/ About Rare Voice Rare Patient Voice is a market research company that helps patients and caregivers voice their opinions, through confidential interviews and surveys, to improve medical products and services. Patients and caregivers receive cash rewards for participating. To show our appreciation, we will send …

View Post

FDA restructures, renames office that reviews cancer therapies

In Clinical Trials by Barbara Jacoby

From: healio.com The FDA office that reviews applications for cancer therapies has been renamed and reorganized. The Center for Drug Evaluation and Research’s Office of Oncologic Diseases — formerly known as the Office of Hematology and Oncology Products — now is structured under terms of a modernization plan approved last fall. Richard Pazdur, MD — who served as director of …

View Post

Scientists crack structure of a novel enzyme linked to cell growth and cancer

In In The News by Barbara Jacoby

By: Iqbal Pittalwala From: University of California Riverside RNA, or ribonucleic acid, is present in the cells of all living beings and required to synthesize proteins. A research team at the University of California, Riverside, has discovered the structure of a novel RNA-modifying enzyme, ZCCHC4, and identified the mechanism that controls how this enzyme recognizes its substrate. ZCCHC4 influences cell …

View Post

Polynoma Presenting Interim Phase III Data for Its Investigational Melanoma Vaccine, Seviprotimut-L

In Clinical Trials by Barbara Jacoby

From: PR Newswire MAVIS Study Identifies Most Responsive Patient Subpopulations, Supporting the Continued Study of Adjuvant Treatment in Localized Melanoma Patients Polynoma LLC, a U.S. immuno-oncology focused biopharmaceutical company and wholly-owned subsidiary of Hong Kong-listed CK Life Sciences Int’l., (Holdings) Inc., is presenting clinical data from MAVIS (Melanoma Antigen Vaccine Immunotherapy Study), its ongoing Phase III clinical study of seviprotimut-L, …

View Post

3D Mammograms: Are They Worth It?

In In The News by Barbara Jacoby

From: cedars-sinai.org Cedars-Sinai Breast Radiologist Explains the Procedure, Who Should Get It and Why If it’s October, it’s Breast Cancer Awareness Month, when pink ribbons sprout up on everything from suit lapels to yogurt containers, reminding women to turn their attention to breast health—especially mammograms. As 3D mammography, also called digital breast tomosynthesis, has become more available nationwide, a big …

View Post

Inovio Demonstrates 80% 6-Month Progression-Free Survival In Phase 2 Glioblastoma Multiforme (GBM) Study with INO-5401 In Combination with PD-1 Inhibitor Libtayo® (cemiplimab)

In Clinical Trials by Barbara Jacoby

Source: Inovio Pharmaceuticals, Inc. 80% of Methylated Patients and 75% of Unmethylated Patients Were Disease Progression-Free at 6 Months Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today positive interim results from Inovio’s Phase 2 study (NCT03491683) of newly diagnosed glioblastoma multiforme (GBM) combining Inovio’s INO-5401, a T cell-activating immunotherapy encoding for three tumor-associated antigens (hTERT, WT1, and PSMA), and INO-9012, an …

View Post

Hormone Therapy for Breast Cancer

In In The News by Barbara Jacoby

By: Elaine K. Howley From: usnews.com This article is based on reporting that features expert sources including Margaret Chen, MD, FACS; Hannah M. Linden, MD There are a variety of ways cancer cells can grow, and for some kinds of breast cancer, hormones feed these wayward cells. Combating the effects of hormones on cancer cells can help slow or stop …